Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22404571 | 1.00 | CA1 (0.46) | CA1CA2CA9CA12PKM | |
| SCHEMBL26245826 | 1.00 | CA1 (0.46) | CA1CA2CA9CA12PKM | |
| SCHEMBL26952600 | 0.89 | L3MBTL1 (0.49) | AGTR2TSHRALDH1A1 | |
| SCHEMBL26952628 | 0.89 | L3MBTL1 (0.49) | AGTR2TSHRALDH1A1 | |
| SCHEMBL5925105 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM | |
| SCHEMBL23970385 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM | |
| SCHEMBL18630954 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM | |
| SCHEMBL15927893 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM | |
| SCHEMBL23970542 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM | |
| SCHEMBL5453543 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-4242204-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242204-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022095975-A1 | CD73 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095975-A1 | CD73 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-12 | — | — | WO | disclosed |
| CN-114437039-A | CD73 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | ENTPD5, ENTPD1, NT5E | CA1 573/4885CA2 539/4885CA9 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.